Skip to main content
. Author manuscript; available in PMC: 2020 Jun 6.
Published in final edited form as: Cell Stem Cell. 2019 May 23;24(6):974–982.e3. doi: 10.1016/j.stem.2019.05.003

Table 2. Proportion of patients with double and triple positive cells and 95% confidence intervals for all 18 patients.

Proportion and 95% confidence intervals of patients positive for double (Nestin+PCNA+, Nestin+Sox2+, DCX+PCNA+) or triple (Nestin+Sox2+Ki67+) immunolabeled cells in brain sections of humans participated in this study.

Total
95% Confidence Interval
Proportion Lower Bound Upper Bound
Nestin+PCNA+ 0.333 0.12 0.97
Nestin+Sox2+ 0.778 0.7 1
Nestin+Sox2+Ki67+ 0.5 0.26 1
DCX+PCNA+ 0.5 0.09 1